TY - JOUR
T1 - Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer
AU - Plaugher, Daniel R.
AU - Childress, Avery R.
AU - Gosser, Christian M.
AU - Esoe, Dave Preston
AU - Naughton, Kassandra J.
AU - Hao, Zhonglin
AU - Brainson, Christine F.
N1 - Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2024/11/28
Y1 - 2024/11/28
N2 - Lung cancer is the leading cause of cancer-related death worldwide, with poor outcomes even for those diagnosed at early stages. Current standard-of-care for most non-small cell lung cancer (NSCLC) patients involves an array of chemotherapy, radiotherapy, immunotherapy, targeted therapy, and surgical resection depending on the stage and location of the cancer. While patient outcomes have certainly improved, advances in highly personalized care remain limited. However, there is growing excitement around harnessing the power of tumor-infiltrating lymphocytes (TILs) through the use of adoptive cell transfer (ACT) therapy. These TILs are naturally occurring, may already recognize tumor-specific antigens, and can have direct anti-cancer effect. In this review, we highlight comparisons of various ACTs, including a brief TIL history, show current advances and successes of TIL therapy in NSCLC, discuss the potential roles for epigenetics in T cell expansion, and highlight challenges and future directions of the field to combat NSCLC in a personalized manner.
AB - Lung cancer is the leading cause of cancer-related death worldwide, with poor outcomes even for those diagnosed at early stages. Current standard-of-care for most non-small cell lung cancer (NSCLC) patients involves an array of chemotherapy, radiotherapy, immunotherapy, targeted therapy, and surgical resection depending on the stage and location of the cancer. While patient outcomes have certainly improved, advances in highly personalized care remain limited. However, there is growing excitement around harnessing the power of tumor-infiltrating lymphocytes (TILs) through the use of adoptive cell transfer (ACT) therapy. These TILs are naturally occurring, may already recognize tumor-specific antigens, and can have direct anti-cancer effect. In this review, we highlight comparisons of various ACTs, including a brief TIL history, show current advances and successes of TIL therapy in NSCLC, discuss the potential roles for epigenetics in T cell expansion, and highlight challenges and future directions of the field to combat NSCLC in a personalized manner.
KW - Adoptive cell transfer
KW - Non-small cell lung cancer
KW - Tumor-infiltrating lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85205793205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85205793205&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2024.217281
DO - 10.1016/j.canlet.2024.217281
M3 - Review article
C2 - 39369769
AN - SCOPUS:85205793205
SN - 0304-3835
VL - 605
JO - Cancer Letters
JF - Cancer Letters
M1 - 217281
ER -